Conversion to Enteric-Coated Mycophenolate Sodium From Various Doses of Mycophenolate Mofetil: Results of a Prospective International Multicenter Trial in Maintenance Renal Transplant Patients Receiving Cyclosporine

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2856-2859

  Nashan, B ^a   Suwelack, B ^a   Ivens, K ^a   Arns, W ^a   Lhotta, K ^a   Bourbigot, B ^a   Budde, K ^a   Fischer, W ^a   Pietruck, F ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRAFT REJECTION; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGINA PECTORIS; ARTICLE; BOWEN DISEASE; BREAST FIBROADENOMA; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRICHOSIS; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG ALVEOLITIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASTITIS; MOUTH INFECTION; MULTICENTER STUDY; NAUSEA; NONHODGKIN LYMPHOMA; NUTRITIONAL DISORDER; OPEN STUDY; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RHINITIS; SHOULDER PAIN; SINGLE BLIND PROCEDURE; SURGICAL PATIENT; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; REOPERATION; TABLETS, ENTERIC-COATED; TIME FACTORS; TISSUE DONORS;

EID: 33750950096     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.118     Document Type: Article

References (17)

1. Sollinger H.W. US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
3. Ojo A., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405
4. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75 (2003) 1341
5. Hardinger K.L., Brennan D.C., Lowell J., et al. Long-term outcomes of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 17 (2004) 609
6. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate dosing patterns on clinical outcomes after renal transplantation. Clin Transplant 17 (2003) 200
7. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
8. Schnitzler M.A., Hardinger K.L., Burroughs T.E., et al. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 5 Suppl 11 (2005) 242
9. Arns W., Breuer S., Choudhury S., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19 (2005) 199
10. Budde K., Glander P., Diekmann F., et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5 (2004) 1333
11. Salvadori M., Holzer H., de Mattos A., et al., ERL B301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
12. Salvadori M., Holzer H., Civati G., et al. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) is safe in kidney transplant patients. Clin Nephrol 66 (2006) 112
13. Budde K., Curtis J., Knoll G., et al., ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 4 (2004) 237
14. Budde K., Knoll G., Curtis J., et al. Long-term safety and efficacy after conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Clin Nephrol 66 (2006) 103
15. Abbud-Filho M., Girón F., Hernández E., et al., Myproms Latam Study Group. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study. Transplant Proc 36 (2004) 1647
16. Chan L.K., Mulgaonkar S., Walker S., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290
17. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31